Method of attenuating reactions to skin irritants
AssigneeDana-Farber Cancer Institute, Inc.
InventorsS. Brian Wilson, Glenn Dranoff, Silke Gillessen
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a method of inhibiting CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Compositions of the invention are useful for the attenuation of CD1d-restricted immune responses, including treatment of skin disorders due to hyperactive immune responses (e.g., contact hypersensitivity), for systemic administration to attenuate ongoing immune responses, and to provide hypoallergenic cosmetic products including pharmaceutical, cosmetic, and skin care compositions. Preferably, these compositions are in a form intended for topical administration.
Claims23
A composition that comprises (a) an agent that attenuates CD1d-restricted NK T cells responses, wherein the agent is selected from the group consisting of antagonists that bind CD1d and inhibit activation of CD1d-restricted NK T cells, agents that block CD1d-specific receptors and CD1d decoys and (b) a pharmaceutically acceptable carrier or diluent.
The composition of claim 4, wherein the phospholipid is selected from the group consisting of 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine (DPPE), 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Poly(ethylene glycol) 2000] (DPPE-PEG), and phophotidyl inositol.
A method of attenuating CD1d-restricted NK T cells responses, comprising administering to a subject a composition that comprises an agent that attenuates CD1d-restricted NK T cells responses, wherein the agent is selected from the group consisting of antagonists that bind CD1d and inhibit activation of CD1d-restricted NK T cells, agents that block CD1d-specific receptors on NK T cells, and decoys and mimics.
A method of preventing or reducing a CD1d-restricted NK T cells' responses, comprising administering to a subject prior to exposure to an irritant a composition that comprises an agent that attenuates CD1d-restricted NK T cells responses, wherein the agent is selected from the group consisting of antagonists that bind CD1d and inhibit activation of CD1d-restricted NK T cells, agents that block CD1d-specific receptors on NK T cells, and decoys and mimics.
Dependencies are inferred from the claim text.